Articolul precedent |
Articolul urmator |
276 1 |
Ultima descărcare din IBN: 2024-02-22 23:52 |
SM ISO690:2012 DANG, Kanishk, HUSSAIN, Afnan, CENUŞA, Florin. Pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome Coronavirus 2. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 396. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 396-396 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. First reported in April 2020, PIMS-TS is a multisystemic inflammatory disease provoked 3-4 weeks after SARS-CoV-2 infection affecting 0.5-1% of the pediatric population. It has unknown post-infectious pathogenesis based on genetic susceptibility. Objective of the study. To emphasize the unfolding nature of COVID-19 by describing the current peculiarities of PIMS-TS patients and encourage its continued education. Material and Methods. We performed a literature review of the PubMed and the ScienceDirect databases using the terms “PIMS-TS” and “COVID-19”. We interpreted 15 full-text articles published between June 2020 and June 2021 in the English language. Results. Typical features were fever, gastrointestinal disorders, elevated inflammatory markers, neutrophilia, lymphocytopenia, and signs of cardiac dysfunction, toxic shock syndrome, Kawasaki disease. Diagnostics including echocardiogram, ECG, chest radiograph, CT, MRI determined the etiology of abdominal pain, arrhythmias, myocarditis, and differentiated from other inflammatory diseases. Patients were at risk for complications and often admitted to the intensive care unit. A multidisciplinary team managed them with glucocorticoids, intravenous immunoglobulin, others. Time constraints limited follow-ups, but mortality was 2%. Conclusion. PIMS-TS patients present consequent SARS-CoV-2 infection with severe acute manifestations. They need hospitalization and a multidisciplinary approach for disease management and complication prevention. The review demands further urgent research of the disease |
||||||
Cuvinte-cheie PIMS-TS, MIS-C, SARS-CoV-2, COVID-19, pediatrics, PIMS-TS, MIS-C, SARS-CoV-2, COVID-19, pediatrie |
||||||
|